An OAd armed with GM-CSF was also shown to be greatly enhanced in combination with anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) or anti-PD1 antibodies for the treatment of triple negative breast cancers [37]. This evidence concerns the gene CTLA4 and triple-negative breast carcinoma.